Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**5-(N,N-dimethyl)amiloride hydrochloride** is a small molecule inhibitor of Na+/H+ exchangers (notably the NHE family, such as SLC9A1/NHE1), which are membrane transport proteins that regulate intracellular pH by exchanging intracellular H+ for extracellular Na+[1][4][5][6][8]. By blocking these exchangers, this molecule decreases intracellular pH and can inhibit pH-dependent cellular processes. It also weakly blocks the transient receptor potential ankyrin 1 (TRPA1) channel (IC50 = 80 µM)[4]. The compound is a derivative of amiloride, originally developed as a research tool, and is used widely in laboratory settings for studying ion transport, ischemia, cell volume regulation, and pain signaling[1][4][5][6][8]. 5-(N,N-dimethyl)amiloride hydrochloride is not approved for clinical or veterinary use and is available only as a research chemical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-(n,n-dimethyl)amiloride hydrochloride.